Showing 2471-2480 of 7591 results for "".
- From ASLMS 2025: New Laser Platforms Expand Options for Vascular Rosaceahttps://practicaldermatology.com/news/new-laser-platforms-expand-options-for-vascular-rosacea/2474325/Advanced vascular lasers are transforming the treatment of rosacea by targeting its root cause (chronic vascular dilation) rather than just managing inflammation. At the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, Eric Bernstein, MD, Director of
- Tattoo Removal Trends Revealed in Global Analysis of Over 200,000 Individualshttps://practicaldermatology.com/news/tattoo-removal-trends-revealed-in-global-analysis-of-over-200000-individuals/2474320/Laser tattoo removal is increasingly sought by individuals across the globe, according to new research presented at the American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando. The data were presente
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Alemtuzumab Highly Effective in CTCL Without Papular History: Analysishttps://practicaldermatology.com/news/study-alemtuzumab-highly-effective-in-ctcl-without-papular-history/2474209/A new analysis suggests the absence of papules, plaques, and tumors (PPT) in cutaneous T-cell lymphoma (CTCL) may predict favorable clinical outcomes with low dose alemtuzumab (LDA) therapy. In a retrospective cohort study
- Report: 5-FU and Imiquimod Combo May Offer Enhanced Actinic Keratosis Clearancehttps://practicaldermatology.com/news/report-5-fu-and-imiquimod-combo-may-offer-enhanced-actinic-keratosis-clearance/2474234/Combining 5-fluorouracil (5-FU) and imiquimod may enhance therapeutic efficacy for actinic keratoses (AK), according to emerging data. "To date, the combination of 5-FU and imiquimod, 2 of the most used monotherapies, remain
- FDA Approves Dupilumab for CSU in Adults 12 and Olderhttps://practicaldermatology.com/news/FDA-Approves-Dupilumab-CSU-Adults-12-Older/2474212/The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with histamine-1 (H1) ant
- Study: AD Patients Switching From Dupilumab to Upadacitinib Have Improved EASI, Itch Scoreshttps://practicaldermatology.com/news/Study-AD-Patients-Switching-From-Dupilumab-Upadacitinib-Have-Improved-EASI-Itch-Scores/2474207/Treatment of moderate-to-severe atopic dermatitis (AD) with upadacitinib in patients who received dupilumab for 16 weeks without an adequate response demonstrated improved efficacy in skin and itch endpoints, according to new research. “Switching from Dupilumab to Upadacitinib in Adults an
- Metabolomic Signature Predictive of Ocular Side Effects in Dupilumab-Treated AD: Studyhttps://practicaldermatology.com/news/metabolomic-signature-may-predict-ocular-side-effects-in-dupilumab-treated-atopic-dermatitis-study/2474199/New research suggests baseline metabolic differences may help predict which patients with atopic dermatitis (AD) are most likely to develop ocular complications from dupilumab. In findings published in
- Study: Strontium May Help Alleviate Pruritus for HS Patientshttps://practicaldermatology.com/news/Study-Strontium-May-Help-Alleviate-Pruritus-HS-Patients/2474128/Strontium cream demonstrated promise as a therapeutic option for managing pruritus in hidradenitis suppurativa (HS), according to a new research article published in the Journal of Clinical and Aesthetic Dermatology. In a prospective, open-label, real-world study involving 50 part
- ICONIC-LEAD: Oral Icotrokinra Clears Skin in 75% of Adolescents with Plaque Psoriasishttps://practicaldermatology.com/news/oral-icotrokinra-clears-skin-in-75-of-adolescents-with-plaque-psoriasis/2474078/Icotrokinra, an investigational oral IL-23 receptor antagonist, led to completely clear skin in 75% of adolescents with moderate-to-severe plaque psoriasis by week 24, according to results presented at the 2025 World Congress of Pediatric Dermatology.